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Adverse drugs events (ADEs) detection constitutes a considerable concern in patient safety and public
health care. For this reason, it is important to develop methods that improve ADE signal detection in
pharmacovigilance databases. Our objective is to apply 3D pharmacophoric similarity models to enhance
ADE recognition in Offsides, a pharmacovigilance resource with drug-ADE associations extracted from the
FDA Adverse Event Reporting System (FAERS). We developed a multi-ADE predictor implementing 3D
drug similarity based on a pharmacophoric approach, with an ADE reference standard extracted from the
SIDER database. The results showed that the application of our 3D multi-type ADE predictor to the
pharmacovigilance data in Offsides improved ADE identification and generated enriched sets of drug-ADE
signals. The global ROC curve for the Offsides ADE candidates ranked with the 3D similarity score showed
an area of 0.7. The 3D predictor also allows the identification of the most similar drug that causes the ADE
under study, which could provide hypotheses aboutmechanisms of action andADE etiology. Ourmethod is
useful in drug development, screening potential adverse effects in experimental drugs, and in drug safety,
applicable to the evaluation of ADE signals selected through pharmacovigilance data mining.
P
ost-marketing unexpected adverse drugs events (ADEs) cause an important damage in patient health with
the consequent risk for patients and high care expenses1,2. For this reason, an early detection of the ADEs is
an urgent objective to improve the functionality of the health-care system. Different regulatory actions can
be carried out once unexpected ADEs are detected that go from warnings in drug labels to the drug withdrawal
from the market. Moreover, ADEs are an important cause for the high degree of attrition in experimental drugs
and an early detection can help to save efforts in the drug development process3.
Different types of computational approaches using protein target and pathway data have been published to
discover associations between drugs and ADEs or possible mechanisms of action for the adverse reactions4,5.
Cheminformatic ligand-based approaches exploiting the idea that similar molecules have similar properties have
also been applied in the assessment of adverse drug reactions6. Computer-aidedmethods are very useful to predict
toxicological effects and select candidates in the drug development process without undesirable properties. As an
example, multiple quantitative structure activity/property relationship (QSAR/QSPR) models have been estab-
lished to predict a variety of toxicological properties7, such as carcinogenicity8 or reproductive and developmental
toxicity9, as well as different types of absorption, distribution, metabolism and excretion (ADME) properties, i.e.
aqueous solubility, plasma protein binding or blood-brain barrier penetration10,11. However, the prediction of
complex clinical adverse events offers important limitations due to the variety of possible mechanism of actions
responsible for the occurrence of the ADE in a patient7. Despite this fact, in silicoQSAR/QSPRmodels have been
developed from preclinical and clinical data to improve the early prediction of different complex ADEs, such as
QT prolongation, phospholipidosis or hepatotoxicity12. Some studies integrated adverse drug reactions data with
cheminformatic fingerprint-based modeling through the use of Laplacian-modified Bayesian models, nearest
neighbor, support vector machines or correlation analysis, among others13–15. Themodels showed applicability in
preclinical safety pharmacology and prediction of adverse drug reactions.
Moreover, applicability of these methods goes beyond experimental drugs and they have also shown potential
as safety tools applied to drugs already in the market through the signal detection enhancement in pharmacov-
igilance studies16,17. In reference to this topic, different pharmacovigilance methodologies have been applied to
study and discover clinical ADEs caused by drugs in the market. The majority of these pharmacovigilance
methods extract signals or drug-ADE associations generated through data mining of health-care databases, such
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Although the analysis of pharmacovigilance data offers great poten-
tial and good results in the identification of adverse effects19–23, the
existence of confounding factors reduce the efficiency of this type of
methods20. As it was shown previously, the existent methods still
provide a high false positives candidates rate that makes difficult
the signal interpretation. However, alternative analysis of the selected
drug-ADE signals provided by cheminformatic approaches can
improve the signal detection generating sets of enriched drug-ADE
candidates. In previous studies, we achieved a significant signal
enhancement in FAERS and EHRs through the use of molecular
fingerprint-based modeling in the study of complex ADEs, such as
rhabdomyolysis and pancreatitis16,17. Other types of similarities, such
as 3D pharmacophoric similarity, adverse event profile similarity
and target profile similarity also yielded models with applications
in pharmacovigilance signal detection24.
In this study we generated a large scale multi-type drug-ADE
predictor integrating 3D molecular structure similarity extracted
through a pharmacophoric approach with a reference standard of
multiple drug-ADEs associations extracted from SIDER database25.
The multi-type drug-ADE predictor can be applicable under differ-
ent scenarios: 1) ADE screening of candidates as experimental drugs
in the development process, and 2) with important implications in
the pharmacovigilance of drugs already existent in the market
through the re-evaluation of drug safety signals extracted from phar-
macovigilance data mining studies. Moreover, the nature of the
multi-ADE predictor allows the researcher to identify for each can-
didate the most similar drug in the reference standard along with the
available ADE information. This fact can lead in some cases to the
establishment of hypothesis for the drug candidates about possible
mechanism of action related to the ADEs.
Our results showed that the implementation at large scale of 3D
cheminformatic models in drug safety data is helpful in signal detec-
tion and facilitates the decision making to further study some of the
selected candidates. Figure 1 illustrates the flowchart followed in the
development of the current study.
Methods
3D pharmacophoric similarity data (matrix Ma). Drug structure preparation: We
downloaded the drug structures from DrugBank26. Proteins and large peptides were
not included in the calculation due to the complexity to determine the most stable 3D
molecular structures. Drugs were mapped to the SIDER database (our reference
standard) establishing 853 drugs by which pharmacophoric data was calculated.
DrugBank provided the bioactive conformations with specified chiral centers for
some drugs. When no chirality information is available, we generated a maximum of
three enantiomers for each drug using the module LigPrep from the Schro¨dinger
package [Schro¨dinger, version 9.2, LLC, New York, USA, 2011]. We also generated
different drug protonation states depending on the pH57.0. Geometry of the
different structures was initially optimized.
Conformational analysis:Weperformed a conformational analysis for all the drugs
using the module Macromodel from Schro¨dinger. The calculation was performed in
water as an implicit solvent to diminish possible intra-molecular forces and generate
more extended conformations more in accordance with biologically active structures.
Non-bonded cut-off distances were extended to 4.0, 8.0 and 20.0 A˚ for H-bond, van
der Waals and electrostatic forces respectively. The selected conformational search
engine was Monte Carlo Multiple Minimum (MCMM). For simplicity, only the
global minimum energy structure according to the OPLS_2005 force field was
retained for the next step.
Shape screening and similarity searching: shape screening calculations were per-
formed using the Phase module from Schro¨dinger package [Schro¨dinger, version 9.2,
LLC, New York, USA, 2011]. In the calculation we used the 3D molecular structures
determined through the previous conformational analysis as templates. Each drug
conformation under evaluation was aligned to each 3D template identifying similar
shape and pharmacophoric features between each pair of drugs. A 3D similarity score
(Phase Sim property) between each pair of drugs was calculated using as a volume
scoring the pharmacophoric type. The structures are treated as sets of pharmaco-
phore sites with a radius of 2 A˚. The 3D score measures the overlap volume between
pharmacophoric sites of the same type present in both drugs and ranges from 0
(maximum dissimilarity) to 1 (maximum similarity). The calculated 3D score
between the structures A and B is defined as:
Sim A,Bð Þ~ O A,Bð Þ
max O A,Að Þ,O B,Bð Þð Þ
where O(A,B) is the pharmacophoric overlap between the structure A and structure B
and max(O(A,A),O(B,B)) is the maximum of the self-overlaps.
Construction of 3D similarity matrix (matrix Ma):We integrated all 3D similarity
scores between pairs of drugs (Phase Sim property) in an 8533853 drug-drug sim-
ilarity matrix called Ma. In this matrix, rows and columns heads represent drugs and
each cell includes the similarity between drugs. Values in the diagonal representing
similarity of each drug against itself are set 0; through this step we will generate a
leave-one-out procedure in the posterior development of the 3D predictor.
ADE reference standard (matrix Mb). SIDER25 resource was used as the initial
reference standard for drug-ADE associations. SIDER is a database with 4,192 side
effects related to 996 drugs with 99,423 drug-ADE associations (prevalence50.024).
Side effect information is extracted from package inserts, drug labels and public
documents. Although more studies would be necessary to confirm some adverse
reactions described in SIDER, this database is a valuable source of relationships
between drugs and ADEs. The data was transformed into a drug-ADE binary matrix
Figure 1 | Workflow followed in the development of the current study.
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with the columns representing adverse reactions and the rows the drugs included in
the study. Each cell includes the value 1 if the drug-ADE is present in SIDER or 0 if the
drug-ADE is not described in our initial reference standard. After mapping drugs
between SIDER and DrugBank and considering only ADEs with at least five drugs,
our final matrix Mb contains 853 rows (drugs) and 1,780 columns (ADEs). The
number of drug-ADE associations (value 1 in thematrix) is 87,151 and the prevalence
is 0.057.
Data integration andmulti-ADEmodel development: generation of matrixMc.A
multi-type drug-ADE predictor was generated through the integration of the
previous data (see Figure 2a). We extracted the maximum value in each cell-
summation-array calculated through the multiplication of the matrices Ma (3D
similaritymatrix) byMb (ADE reference standardmatrix). The newmatrix calledMc
contains in each cell the predictive score by each drug-ADE pair.We only retained the
maximum value in each cell-array to generate only one leave-one-out score for each
drug-ADE pair, provided by themost similar drug that causes the ADE. However, the
method allows the implementation of alternative algorithms. Figure 2b shows how
the integration of the data generated a final multi drug-ADE predictor. For instance,
drug (a) that causes the ADE 1 in the example generates as a candidate the pair ‘‘ADE
1-drug (c)’’ with a score of 0.9, which is the 3D similarity score between drug (a)
and (c).
Application of the multi-ADE predictor in pharmacovigilance data. Offsides
database27 was used as the module that provided pharmacovigilance data, an off-label
adverse effects resource with 1,332 drugs and 10,097 adverse effects. This database
was generated previously through mining FAERS18. Offsides provides a set of drug-
ADE cases with the respective Empirical Bayes Geometric Mean (EBGM), t-statistics,
and p-values. Our 3D database extracted from Mc matrix was mapped to the
pharmacovigilance data extracted from Offsides, retaining 53,692 drug-ADE
associations in common.
Evaluation of the performance. We calculated the area under the receiver
operating characteristic (AUROC) curve as a comparative measure of the quality
of the performance in different situations: 1) for the 3D multi-ADE predictor
considering all the generated drug-ADE scorings as an outcome, 2) for the 3D
multi-ADE predictor considering each ADE as an individual outcome 3) for the
global set of drug-ADE associations in common between Offsides and the 3D
predictor as an outcome, and 4) for the drug-ADE associations in common
between both data sources but considering each ADE as an individual outcome for
plotting the results. Box plots were created to visualize the AUROC results for the
individual ADEs. When the 3D model was applied to Offsides, the drug-ADE
associations were ranked according to Empirical Bayes Geometric Mean (EBGM),
t-statistic, p-values and the 3D score. Precision was also calculated in different top
positions to evaluate the quality of the results.
Comparative modeling. 2D MACCS models: ADE models were also generated
integrating a 2D similarity matrix into the ADE reference standard data as explained
previously. For the generation of the 2D similarity matrix, we calculated for each drug
Figure 2 | Panel a) In the drug3ADEmatrix (reference standard) is implemented the 3D drug similarity to develop themulti-ADE predictor. Drugs with
associated ADEs in the reference standard are colored in red. Drugs predicted to be associated with the ADEs are colored in orange (new candidates);
Panel b) Integration of the data in themodel development. In the product of the drug-drug 3D similaritymatrix (Ma) by the drug-ADE reference standard
matrix (Mb) is retained in each cell themaximum value of the array-multiplication and the newmatrix (Mc) containing the drug-ADE scores is obtained.
As an example, ‘‘drug (a)’’ that causes the ‘‘ADE 2’’ is retrieved with a high score of 0.9. At the same time, ‘‘drug (a)’’ associated with the ‘‘ADE 3’’
(new candidate not present in the initial reference standard) is scored also with 0.9.
www.nature.com/scientificreports
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themolecular fingerprintMACCS28. The fingerprint represents eachmolecule as a bit
vector that codifies the presence or non-presence of structural keys (values 1 and 0
respectively). The Tanimoto Coefficient (TC) was calculated to compare drug
fingerprints and generate the 2D similarity matrix. More details about 2D MACCS
similarity can be found in previous publications16.
Quantitative structure-activity relationship (QSAR) models: QSAR models for 10
ADEswere developed. Statistical analyses were performedwith the help of SPSS [IBM
SPSS Statistics forWindows, Armonk, NY: IBMCorp] and R packages [The R Project
for Statistical Computing: http://www.r-project.org]. The database was divided in
training (80% of the data) and test set (20%). We calculated with E-Dragon
[E-Dragon Software, Virtual Computational Chemistry Laboratory: http://www.
vcclab.org/lab/edragon] different types of molecular descriptors, i.e. including
topological and physico-chemical descriptors. In the Linear Discriminant Analysis
(LDA) we used a stepwise method for variable selection. Quality of the obtained
functions was assessed with Fisher ratio (F), Wilks’ statistic (U), level of significance
(p-values) and ROC curves. A maximum of five independent variables (molecular
descriptors) were introduced in the models. A more detailed explanation of the
molecular descriptors can be found in the literature29. The parameters extracted from
the QSAR models are: allergic contact dermatitis (U50.78, F (5,659) 5 38.10,
p , 0.001, descriptors: F-081, nRCO, O-061, nArNO2, nCrq), extrapyramidal
symptoms (U50.82, F (5,659) 5 28.75, p , 0.001, descriptors: nRNR2, nR07,
D/Dr07, nN5C-N,, C-026), hyperpyrexia (U50.91, F (5,659) 5 13.49, p , 0.001,
descriptors: MAXDP, nRNR2, MATS1v, GATS1e, MATS3p), hypertrichosis (U50.80,
F (5,659)5 32.59, p, 0.001, descriptors: nRCO, F-081, C-012, ww, GATS8e), increased
intraocular pressure (U50.88, F (5,659) 5 17.24, p , 0.001, descriptors: nRCO,
EEig15d, nOHp, nCrq, GATS7p), malignant syndrome (U50.88, F (5,659) 5 18.01,
p, 0.001, descriptors: nRNR2, T(O..Br), GATS5e, HNar, MPC09), mydriasis (U50.88,
F (5,659) 5 17.44, p , 0.001, descriptors: Ms, EEig14d, H-047, nN, nR07), paralytic
ileus (U50.73, F (5,659)5 49.94, p, 0.001, descriptors: nR11, nRNR2,Wap, MAXDP,
H-053), pseudotumor cerebri (U50.80, F (5,659) 5 33.85, p , 0.001, descriptors:
nRCO, nOHt, BEHm2, H-051, nCconj), tardive dyskinesia (U50.87, F (5,659)5 18.90,
p , 0.001, descriptors: nRNR2, nN5C-N,, F-084, MAXDP, nIsoxazoles).
Results
Performance of themulti-ADE predictor.We implemented the 3D
drug similarity data in the initial ADE reference standard extracted
from SIDER as described in theMethods. Themodel generates a new
85331,780 drug-ADE matrix with 1,518,340 leave-one-out scores.
Out of the total number of drug-ADE pairs, we labeled as true
positives the initial SIDER drug-ADEs and as false positives the
rest of possible drug-ADE pairs. We showed the area under the
ROC curve (AUROC50.72) in Figure 3a. A validation was carried
out through a hold-out method.We randomly introduced the 80% of
the data in themodel whereas the 20%was extracted to a test set. The
AUROCs for the training and test sets were 0.71 and 0.73
respectively, showing a high degree of stability and agreement with
the leave-one-out method.
Moreover, we also evaluated the performance of the model in each
individual ADE. For each ADE we calculated the AUROC and
showed the results in a box plot (see Figure 3b) with the median
(0.58), the first quartile (0.51) and the third quartile (0.66). The
number of ADE models in each range of AUROC values is repre-
sented in Figure 3c. Out of the 1,780 individual ADE models, 748
and 198 models presented an AUROC greater than 0.6 and 0.75
respectively.
Besides the maximum 3D score used in our models, we evaluated
the performance of alternative 3D algorithms, including a double
similarity score (defined as the difference between the maximum
similarity against the positive and negative groups) and an average
Figure 3 | Panel a) Area under ROC curve for the 3Dmulti-ADE model; Panel b) Box plot of the AUROCs calculated for each individual ADE. Panel c)
Graphic representing number of individual ADE models in each range of AUROC values.
www.nature.com/scientificreports
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score (defined as the average similarity calculated against the positive
group). Alternative algorithms were tested for the top 10models with
at least 25 drugs in the positive group. The data are divided into a
training set (80%) and a test set (20%). Figures 4a and 4b show the
AUROC values for the three algorithms in the 10 selected ADEs
along with a global model including the 10 endpoints. The double
similarity score performs similarly to the 3D maximum score,
whereas the average score yields more limited results (see
Figure 4a). A score including positive and negative controls was
previously used by our research group with good results24.
However, in our reference standard provided by SIDER database,
the non-ADE drugs are really unknown. This fact could be a limita-
tion factor for the use of alternative scores taking into account nega-
tive controls. For this reason, our 3D models are based on the
maximum similarity against the set of drugs that cause the ADEwith
the aim of prioritizing drugs similar to the ADE drugs.
We also compared the performance using other types of similarities
between drugs in the development of ADE predictors. As an example,
AUROC global results for the 3D model were compared against a
model developed using 2D molecular structure similarity, calculated
through MACCS molecular fingerprints28. The global AUROC was
0.77, slightly better than the area determined with the 3D structure
(AUROC50.72). In a similar way as described previously, we
developed QSAR models for the top 10 3D endpoints with at least
25 drugs responsible for the ADE. Molecular descriptors were calcu-
lated with E-Dragon and Linear Discriminant Analysis (LDA) was
used to generate 10 classifier functions. We calculated AUROC curves
using the posterior classification probabilities extracted from the LDA.
Figures 4c and 4d show the AUROC results for the 3D, 2D MACCS
and QSAR modeling for the 10 different ADEs along with a global
model including the 10 endpoints. The database in each ADE is divided
in two sets: training (80%) and test set (20%). The different methods
yielded similar results for the selected models. The average AUROCs
for the 10 ADEs are 0.81, 0.75 and 0.86 in the training with the 3D, 2D
and QSAR models respectively. In the test set, the average AUROC
values are 0.89, 0.85 and 0.84 using 3D, 2D and QSAR modeling.
The different perspective provided by the analysis of the 3D drug
similarity can generate different sets of potential drug-ADE candi-
dates. Figure 5a shows a comparison between the molecular similar-
ities for all the pairs of drugs included in the study calculated using
2D MACCS and 3D methods. As shown in Figure 5a, some similar
pairs are found with 3D methods (the 3D score is 0.7–0.8) and not
detected with high 2D score (the score is 0.3–0.4), and vice versa. We
also compared in Figure 5b the overlap in the 10% top similarities
detected by the 3D method against the 2D approaches (MACCS
fingerprint) for the set of drugs responsible for the ADE hyperpyr-
exia. Although both methods detected some pairs of drugs in com-
mon, there are differences in the detection of drug-drug similarities.
Figure 4 | Panels (4a) and (4b): AUROC values in training and test sets using different algorithms in the 10 selected ADEs along with a global model
including the 10 endpoints (algorithms: maximum similarity against the positive controls, difference between the maximum similarity against positive
and negative controls, and average similarity against the positive controls). Panels (4c) and (4d): AUROC results in training and test sets for the 3D, 2D
MACCS and QSAR modeling in the selected ADEs along with a global model including the 10 endpoints. The 10 selected ADEs are: allergic contact
dermatitis, extrapyramidal symptoms, hyperpyrexia, hypertrichosis, increased intraocular pressure, malignant syndrome, mydriasis, paralytic ileus,
pseudotumor cerebri and tardive dyskinesia.
www.nature.com/scientificreports
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Application of the multi-ADE predictor in Offsides database.We
analyzed 53,692 drug-ADE pairs present in common in the 3D
multi-ADE predictor and Offsides database27 (560 ADEs and 639
drugs in common), a resource of drug-ADE associations extracted
from mining FAERS. As previously, the drug-ADE pairs present in
SIDERwere labeled as TP (7,714 cases) and the pairs not described in
SIDERwere deemed as FP (45,978 cases). The prevalence in the set of
53,692 drug-ADE associations is 0.14. This selected set is an enriched
set of drug-ADE associations compared to the initial reference
standard (matrix Mb) in which the prevalence was 0.057 (enrich-
ment factor52.5).
Drug-ADEs were ranked using the Empirical Bayes Geometric
Mean (EBGM), t-statistic and p-values extracted from Offsides and
using the 3D score provided by our multi-ADE model previously
generated. Although the AUROCs calculated for the individual
ADEs showed similar results between EBGM, t-statistic, p-values
and 3D scores (see Figure 6a with the box plot for all the methods),
the best ranking plotting all the drug-ADE candidates in a global
ROC curve was achieved with the 3D score (Figure 6b). The 3D score
provided by our model showed an AUROC of 0.71, whereas the
global AUROCs for t-statistic and p-values were 0.62 in both cases.
Remarkably, the EBGM algorithm showed a poor performance with
an AUROC50.48. As we have shown above, the EBGM used in
Offsides was a good measurement to extract an enriched set of
drug-ADE candidates, but it does not provide in this analysis the
best approach to rank the drug-ADE associations.
Moreover, the precision in different top positions when all the
drug-ADEs are merged was also analyzed as a comparative measure-
ment (see Table 1 and Figure 6c). The results indicate that ranking
the Offsides candidates with the 3D score is useful to obtain a more
enriched subset of drug-ADE candidates.
Discussion
In this paper, we showed a simple and efficient method to develop a
3D multi-ADE predictor with possible applications in pre-clinical
ADE screenings of experimental drugs, and patient safety through
the evaluation of marketed drugs as ADE candidates extracted from
pharmacovigilance data sources. Although the 3D multi-type pre-
Figure 5 | Comparison between the similarities obtained using 2D MACCS and 3D methods for all the pairs of drugs included in the study (panel a).
Panel b shows the overlap in the top 10% similarities detected by the 3D and 2D approaches (MACCS) for the set of drugs responsible for the ADE
hyperpyrexia. Drug pairs detected by bothmethods are colored in red. In orange is represented the pairs pointed out only by the 2Dmethod. Pairs of drugs
detected by the 3D method in the top 10% are colored in green. The matrix is symmetric and the diagonal is represented in grey.
www.nature.com/scientificreports
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dictor was applied to a set of ADE candidates from mining FAERS
(Offside data), other types of pharmacovigilance resources can be
used, such as Electronic Health Records17. The application of our 3D
multi-ADE predictor to Offsides resource allowed us to obtain
enriched sets of ADE candidates interesting for further study.
Moreover, since the 3D score provided by our models is based on
the maximum similarity against the set of drugs that cause the ADE,
we can isolate the drug that produced the signaling score and analyze
if theADE information available for it could be applicable to our drug
candidate, pointing out possible ADE mechanisms of action.
However, application of other considerations useful to evaluate the
importance of the ADE candidate, such as pharmacological relation-
ships or the study of the candidate in different data resources, is
advisable for a more clear establishment of a ‘‘red flag’’ in the ADE
candidate.
Performance of the 3D multi-ADE predictor is highly depend-
ent on the quality of the initial ADE reference standard used to
develop the model. Different complexity in each ADE of the ref-
erence standard, related to the molecular structure and pharmaco-
logical categories of the drugs collected for each ADE, is
Figure 6 | Data extracted from the drug-ADE associations found in both 3Dmulti-ADEmodel andOffsides database. Panel a) Box plot of the AUROCs
calculated for each individual ADE using different methods to rank the drug-ADE associations: Empirical Bayes Geometric Mean (EBGM), p-values, t-
statistic and our 3D similarity score. Panel b) Comparison of the ROC curves ranking the drug-ADE associations using Empirical Bayes Geometric Mean
(EBGM), p-values, t-statistic and the 3D similarity score. Panel c) Precision achieved for the different methods in top positions 100–1000 (methods:
EBGM, p-values, t-statistic and 3D score were applied to the set 3Dmulti-ADE model1Offsides. The precision using only the 3Dmulti-ADE predictor
without Offsides was also plotted for comparative results). The method that offered the best precision results was 3D score in 3D multi-ADE model 1
Offsides.
Table 1 | Precision of the different methods in top scoring positions
Precision (TP/TP 1 FP)
TOP
position




t-statisticb (Offsides 1 3D
predictor)
p-valuesb (Offsides 1 3D
predictor)
3D scoreb (Offsides 1 3D
predictor)
100 0.34 0.22 0.56 0.60 0.59
200 0.33 0.21 0.53 0.54 0.51
300 0.45 0.20 0.47 0.50 0.51
400 0.48 0.18 0.44 0.45 0.51
500 0.51 0.17 0.43 0.45 0.52
600 0.51 0.17 0.42 0.45 0.51
700 0.52 0.17 0.42 0.43 0.50
800 0.49 0.16 0.41 0.42 0.51
900 0.44 0.16 0.41 0.41 0.50
1000 0.41 0.16 0.39 0.41 0.49
aCandidates generated by the 3D multi-ADE predictor without Offsides ranked according to the 3D score;
bcandidates in common in the 3D multi-ADE predictor and Offsides ranked using EBGM, t-statistic, p-values and 3D score.
www.nature.com/scientificreports
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responsible for an irregular performance since the different ADEs
showed AUROCs from poor to excellent values. With the integ-
ration of 3D pharmacophoric similarity in the SIDER database, we
maximize the pattern ‘‘similar drugs have similar ADEs’’ already
present in some of the studied ADEs, but not in all of them; hence,
the variable performance of the 3D predictor in the individual
ADEs. Moreover, further studies would be necessary to confirm
some drug reactions in our reference standard provided by SIDER
database, and the non-ADE drugs (negative control) are really
unknown. Although SIDER is a very useful publically available
resource, missing data problem is a limitation inherent to the
predictive models developed with the reference data. Prevalence
in SIDER is variable depending on the ADE and spans values
between 0.001 for some reactions, such as abasia, and 0.82 for
the ADE nausea. Additional enhancement in the representative-
ness of the initial reference standard database could improve the
external predictive power in this type of predictor.
Other types of similarities between drugs can be included to
develop ADE models. Pauwels et al.15 developed a multi-ADE pre-
dictor integrating the SIDER database with 2D molecular similarity
information extracted from 2D fingerprints defined in PubChem30.
They integrated the information through the use of different meth-
ods, such as nearest neighbor, support vector machines and canon-
ical correlation analysis. 2D methods showed excellent global ROC
curves and the method showed potential to generate correlated sets
of chemical fragments and adverse effects.
Although the use of 2D molecular structure has been proven to
offer good results avoiding complex calculations, the 3D molecular
structure analysis provides different insights regarding to 2D ana-
lysis. As shown in Figure 5, both methods, 2D and 3D, are able to
detect a diverse chemical space. Some studies also demonstrated
relationships between chemical structures and biological functions
that are not captured with 2D approaches but that become more
detectable using the 3D molecular structure similarity31–33. The dif-
ferent perspective provided by the analysis of the 3D drug similarity
can generate different sets of potential drug-ADE candidates.
For the development of the 3D predictor it is possible the use of
alternative approaches in regards to the methods described in the
current article, i.e. other types of conformational search engines,
different algorithms for molecular alignment or the applicability of
alternative similarity scoring functions. In this study, for simplicity,
only the global minimum energy structure generated by the confor-
mational analysis was retained as representative of the calculation.
However, it is worth to point out that inmany occasions the bioactive
conformations of the molecules binding the protein are not captured
with the simple retention of the global minimum energy conforma-
tion34. In some cases, it could be more convenient to retain more
conformations extracted from the MCMM to detect with more pre-
cision the bioactive bound form of the drug. With the aim of per-
forming a comparative study, we collected from the Protein Data
Bank35 the 3D co-crystallized structure of 158 drugs included in
our data bound to protein targets. We superimposed and measured
the root mean square deviation (RMSD) between the global min-
imum energy 3D structures generated through the MCMM confor-
mational analysis and the co-crystallized drug structures (see
Figure 7). A comparative study was carried out taking into account
the top 10 3D minimum energy conformations generated by the
MCMM. Out of the 10 conformations, the best RMSD against the
crystallized drugs is plotted in Figure 7. The average RMSD using the
first and the second protocol are 1.66 and 1.05 respectively. The
second protocol offered better RMSD results achieving drug confor-
mations more in accordance with the co-crystallized bioactive con-
formations. However, it is still a challenge to predict which of the ten
conformations is the closest to the crystallized drug conformation,
increasing the complexity in posterior calculations. Moreover, the
protocol followed in this study, considering only the minimum
energy structure, is simpler and presented acceptable RMSD values
compared to co-crystallized structures (112 out of 158 structures
with a RMSD lower than 2). It is also worth noting than drugs could
present different bioactive conformations depending on the receptor
they are bound to. In fact, many ADEs are due to the interaction
between drugs and off-targets with possible different drug confor-
mational states depending on the target. Although docking simula-
tions could be a method to calculate the 3D drug conformations,
off-targets responsible for the ADEs are in many cases unknown
due to the lack of information in ADE mechanisms of action.
In this article, we developed a 3D multi-ADE predictor based on
the integration of 3D pharmacophoric similarity into an ADE ref-
erence standard provided by SIDER database. Combination of the
3D predictor with pharmacovigilance data allowed a better prioriti-
zation of multiple ADE candidates and the generation of enriched
sets of ADE signals. These types of predictors are promising tools to
analyze data from pharmacovigilance studies and rationalize the
results. The method is simple and efficient, applicable to ADE large
scale detection, and can help in the ADE decision making process to
select some candidates for further studies.
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